Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Add To Watchlist

Recent & Breaking News (NDAQ:AGIO)

Agios Reports Second Quarter 2016 Financial Results

GlobeNewswire August 4, 2016

Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016

GlobeNewswire July 28, 2016

Flagship Ventures Names Daniel McIntyre Partner

PR Newswire June 29, 2016

The Market In 5 Minutes: Microsoft-LinkedIn, And Some Major iPhone News

Benzinga.com June 13, 2016

10 Stocks Moving In Monday's Pre-Market Session

Benzinga.com June 13, 2016

AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency

GlobeNewswire June 11, 2016

11 Biggest Mid-Day Losers For Thursday

Benzinga.com June 9, 2016

Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers

GlobeNewswire June 9, 2016

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma

PR Newswire June 2, 2016

Agios to Host Conference Call from the 21st Congress of the European Hematology Association

GlobeNewswire June 1, 2016

Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association

GlobeNewswire May 19, 2016

Evogene Reports Financial Results for the First Quarter of 2016

GlobeNewswire May 19, 2016

Agios Updates 2016 Financial Guidance

GlobeNewswire May 17, 2016

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement

GlobeNewswire May 17, 2016

Agios Reports First Quarter 2016 Financial Results

GlobeNewswire May 5, 2016

Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016

GlobeNewswire May 2, 2016

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

GlobeNewswire March 30, 2016

Agios to Present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8

GlobeNewswire March 1, 2016

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

GlobeNewswire February 18, 2016

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2015 Financial Results on February 18, 2016

GlobeNewswire February 11, 2016